azosemide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diuretics, furosemide derivatives 278 27589-33-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • azosemide
  • diurapid
  • azosemid
  • Molecular weight: 370.83
  • Formula: C12H11ClN6O2S2
  • CLOGP: 1.36
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 126.65
  • ALOGS: -3.59
  • ROTB: 5

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 10 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 1.48 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
Vd (Volume of distribution) 0.28 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK1,GRK2,GRK3,GSK3B,IGF1R,ITK,MAP3K21,MAPK1,MAPK7,MAPK9,MAPKAPK2,MARK4,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,SIK2,SIK3,STK33,TEK,TTK 36
kinase-selectivity-class AXL,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAP3K21,MAPK7,PDK1,PIK3CB,SIK2,STK33 11
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 384.92 26.97 172 5731 109324 90513220
Renal impairment 231.26 26.97 120 5783 105301 90517243
Cardiac failure chronic 201.13 26.97 51 5852 5595 90616949
Brain natriuretic peptide increased 100.66 26.97 30 5873 5975 90616569
Blood pressure decreased 98.24 26.97 61 5842 74834 90547710
Anaemia 92.27 26.97 114 5789 352688 90269856
Hepatic function abnormal 90.82 26.97 49 5854 46239 90576305
Pulmonary arterial hypertension 88.03 26.97 40 5863 26147 90596397
Cerebral infarction 87.43 26.97 40 5863 26556 90595988
Dehydration 84.24 26.97 82 5821 194365 90428179
Pulmonary congestion 82.55 26.97 35 5868 19398 90603146
Cardiac failure acute 80.46 26.97 30 5873 11899 90610645
Pleural effusion 67.69 26.97 57 5846 111934 90510610
Concomitant disease aggravated 66.99 26.97 26 5877 11492 90611052
Right ventricular failure 66.64 26.97 30 5873 19175 90603369
Pulmonary hypertension 61.78 26.97 37 5866 42486 90580058
Hyperkalaemia 58.75 26.97 42 5861 64922 90557622
Fatigue 51.95 26.97 7 5896 1154016 89468528
Cardiac failure congestive 51.09 26.97 46 5857 98648 90523896
Platelet count decreased 50.52 26.97 53 5850 136916 90485628
Hypernatraemia 50.40 26.97 20 5883 9367 90613177
Atrial fibrillation 49.82 26.97 52 5851 133559 90488985
Hyperuricaemia 45.67 26.97 17 5886 6702 90615842
Drug ineffective 45.26 26.97 17 5886 1384281 89238263
Hypokalaemia 43.54 26.97 48 5855 131068 90491476
Upper respiratory tract inflammation 43.26 26.97 13 5890 2659 90619885
Interstitial lung disease 40.29 26.97 36 5867 76369 90546175
Aortic valve stenosis 37.36 26.97 13 5890 4227 90618317
Oedema peripheral 35.93 26.97 62 5841 257853 90364691
Pneumonia aspiration 35.92 26.97 26 5877 40914 90581630
Iron deficiency anaemia 35.42 26.97 21 5882 23641 90598903
Altered state of consciousness 32.26 26.97 22 5881 31510 90591034
Haemorrhage subcutaneous 32.20 26.97 11 5892 3385 90619159
Mitral valve incompetence 31.16 26.97 19 5884 22505 90600039
Embolic stroke 30.25 26.97 11 5892 4061 90618483
Spinal compression fracture 29.55 26.97 16 5887 15162 90607382
Marasmus 27.16 26.97 7 5896 816 90621728

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 361.23 23.60 206 5494 106650 42508985
Renal impairment 212.02 23.60 149 5551 110079 42505556
Cardiac failure chronic 130.94 23.60 49 5651 9552 42606083
Hepatic function abnormal 76.95 23.60 60 5640 51507 42564128
Blood pressure decreased 76.67 23.60 63 5637 58269 42557366
Cerebral infarction 71.19 23.60 47 5653 31122 42584513
Concomitant disease aggravated 69.80 23.60 28 5672 6558 42609077
Altered state of consciousness 66.53 23.60 44 5656 29215 42586420
Pneumonia aspiration 61.46 23.60 52 5648 50026 42565609
Dehydration 54.47 23.60 80 5620 141687 42473948
Brain natriuretic peptide increased 52.35 23.60 23 5677 6747 42608888
Pulmonary arterial hypertension 52.09 23.60 26 5674 10161 42605474
Interstitial lung disease 48.46 23.60 56 5644 78406 42537229
Hyperkalaemia 45.66 23.60 55 5645 80403 42535232
Right ventricular failure 44.80 23.60 23 5677 9532 42606103
Low cardiac output syndrome 42.28 23.60 11 5689 643 42614992
Cardiac failure acute 39.73 23.60 24 5676 13609 42602026
N-terminal prohormone brain natriuretic peptide increased 37.69 23.60 15 5685 3438 42612197
Oedema peripheral 34.87 23.60 64 5636 136012 42479623
Pleural effusion 34.64 23.60 53 5647 97113 42518522
Marasmus 34.34 23.60 10 5690 889 42614746
Pemphigoid 32.93 23.60 20 5680 11447 42604188
Oedema 31.88 23.60 37 5663 51964 42563671
Drug ineffective 31.74 23.60 23 5677 630174 41985461
Atrial fibrillation 31.25 23.60 62 5638 139531 42476104
Pulmonary hypertension 29.97 23.60 25 5675 23544 42592091
Cardiothoracic ratio increased 29.21 23.60 5 5695 35 42615600
Fatigue 29.12 23.60 11 5689 435630 42180005
Decreased appetite 28.87 23.60 73 5627 193064 42422571
Subdural haematoma 28.30 23.60 24 5676 23114 42592521
Gastric cancer 27.76 23.60 15 5685 6888 42608747
Haemorrhage subcutaneous 27.17 23.60 11 5689 2635 42613000
Hyperuricaemia 25.94 23.60 16 5684 9408 42606227
Hypernatraemia 25.02 23.60 16 5684 10016 42605619
Cardiac failure congestive 24.12 23.60 42 5658 85560 42530075

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure 672.89 22.96 348 11362 187278 110390311
Renal impairment 422.18 22.96 257 11453 188188 110389401
Cardiac failure chronic 282.57 22.96 90 11620 13721 110563868
Hepatic function abnormal 164.91 22.96 108 11602 89187 110488402
Blood pressure decreased 151.28 22.96 113 11597 114978 110462611
Cerebral infarction 150.91 22.96 84 11626 51754 110525835
Brain natriuretic peptide increased 138.32 22.96 50 11660 11159 110566430
Pulmonary arterial hypertension 132.43 22.96 66 11644 32502 110545087
Dehydration 131.92 22.96 155 11555 279356 110298233
Concomitant disease aggravated 130.14 22.96 53 11657 16311 110561278
Cardiac failure acute 104.44 22.96 51 11659 24027 110553562
Right ventricular failure 103.75 22.96 52 11658 25902 110551687
Hyperkalaemia 99.03 22.96 95 11615 135701 110441888
Pneumonia aspiration 94.04 22.96 74 11636 81159 110496430
Interstitial lung disease 91.40 22.96 92 11618 139242 110438347
Anaemia 90.79 22.96 187 11523 546899 110030690
Altered state of consciousness 90.32 22.96 63 11647 57563 110520026
Pulmonary hypertension 88.02 22.96 61 11649 55159 110522430
Pleural effusion 86.14 22.96 100 11610 177609 110399980
Pulmonary congestion 81.51 22.96 47 11663 30919 110546670
Fatigue 79.94 22.96 16 11694 1215942 109361647
Atrial fibrillation 79.15 22.96 109 11601 229533 110348056
Hypernatraemia 72.06 22.96 36 11674 17797 110559792
Drug ineffective 70.26 22.96 37 11673 1520503 109057086
Cardiac failure congestive 69.88 22.96 83 11627 150917 110426672
Hyperuricaemia 69.75 22.96 33 11677 14498 110563091
Marasmus 65.18 22.96 18 11692 1673 110575916
Platelet count decreased 62.89 22.96 98 11612 230345 110347244
Oedema peripheral 61.18 22.96 118 11592 328542 110249047
Haemorrhage subcutaneous 54.74 22.96 21 11689 5518 110572071
Iron deficiency anaemia 50.60 22.96 35 11675 31524 110546065
Low cardiac output syndrome 48.35 22.96 13 11697 1093 110576496
Pain 47.39 22.96 21 11689 954934 109622655
Subdural haematoma 46.07 22.96 35 11675 36419 110541170
Aortic valve stenosis 45.17 22.96 19 11691 6331 110571258
Decreased appetite 42.92 22.96 129 11581 475717 110101872
Embolic stroke 42.40 22.96 20 11690 8723 110568866
Pneumonia bacterial 41.80 22.96 29 11681 26232 110551357
Pemphigoid 41.70 22.96 26 11684 19681 110557908
Cardiothoracic ratio increased 39.61 22.96 7 11703 78 110577511
N-terminal prohormone brain natriuretic peptide increased 39.20 22.96 17 11693 6104 110571485
Hypokalaemia 38.26 22.96 69 11641 182379 110395210
Disseminated intravascular coagulation 38.11 22.96 33 11677 41253 110536336
Upper respiratory tract inflammation 37.65 22.96 15 11695 4356 110573233
Drug hypersensitivity 36.85 22.96 3 11707 454087 110123502
Oedema 36.13 22.96 73 11637 209903 110367686
Gastric cancer 35.21 22.96 19 11691 10989 110566600
Enterocolitis 35.13 22.96 23 11687 18926 110558663
Concomitant disease progression 33.24 22.96 13 11697 3597 110573992
Cardiac dysfunction 32.55 22.96 15 11695 6208 110571381
Pneumonia 32.35 22.96 180 11530 876534 109701055
Blood urea increased 31.87 22.96 34 11676 54923 110522666
Embolic cerebral infarction 31.55 22.96 10 11700 1496 110576093
Spinal compression fracture 30.90 22.96 21 11689 18371 110559218
Hypotension 30.62 22.96 123 11587 523726 110053863
Physical deconditioning 29.98 22.96 12 11698 3525 110574064
Asthenia 29.90 22.96 18 11692 688981 109888608
Dyspnoea exertional 29.39 22.96 45 11665 104015 110473574
Hypersensitivity 29.36 22.96 4 11706 403994 110173595
Pulmonary alveolar haemorrhage 29.17 22.96 21 11689 20129 110557460
Ventricular tachycardia 29.11 22.96 31 11679 49978 110527611
Immobilisation syndrome 27.75 22.96 8 11702 868 110576721
Mitral valve incompetence 27.50 22.96 25 11685 33304 110544285
Sinus node dysfunction 27.23 22.96 15 11695 9032 110568557
Urine output decreased 27.15 22.96 20 11690 19856 110557733
Peripheral swelling 27.11 22.96 5 11705 404029 110173560
Atrial tachycardia 27.03 22.96 15 11695 9163 110568426
Swelling 26.67 22.96 3 11707 351038 110226551
Bradycardia 26.66 22.96 54 11656 155463 110422126
Chronic kidney disease 25.91 22.96 36 11674 76255 110501334
Blood creatinine increased 25.05 22.96 58 11652 182831 110394758
Hepatic encephalopathy 24.90 22.96 22 11688 28234 110549355
Transfusion 24.81 22.96 21 11689 25451 110552138
Glomerular filtration rate decreased 24.44 22.96 22 11688 28934 110548655
Depressed level of consciousness 24.21 22.96 43 11667 112235 110465354
Renal disorder 24.19 22.96 28 11682 49451 110528138
Nephrogenic anaemia 23.83 22.96 11 11699 4566 110573023
Anxiety 23.74 22.96 4 11706 345074 110232515
Alopecia 23.45 22.96 5 11705 364748 110212841
Arthralgia 23.34 22.96 29 11681 779603 109797986

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D004232 Diuretics
CHEBI has role CHEBI:77608 loop diuretic

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Congestive heart failure indication 42343007 DOID:6000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.68 acidic
pKa2 10.12 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01323 KEGG_DRUG
18651 RXNORM
C0052820 UMLSCUI
CHEBI:31248 CHEBI
IWE PDB_CHEM_ID
CHEMBL1097235 ChEMBL_ID
DB08961 DRUGBANK_ID
C018222 MESH_SUPPLEMENTAL_RECORD_UI
2273 PUBCHEM_CID
3954 INN_ID
MR40VT1L8Z UNII
007033 NDDF

Pharmaceutical products:

None